OS Therapies Inc. 10-Q Summary: Quarter Ended September 30, 2024
Business Context and Reporting Period
OS Therapies Inc. (OSTX) is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors. The reporting period covers the three and nine months ended September 30, 2024. The Company is an emerging growth company and a smaller reporting company. As of September 30, 2024, the Company had one ongoing clinical trial for its lead product candidate, OST-HER2, which achieved full enrollment in October 2023. The Company consummated its Initial Public Offering (IPO) on August 2, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2,875,232) | $(1,974,990) | $(5,891,704) | $(6,327,016) |
| Loss per Share (Basic & Diluted) | $(0.18) | $(0.38) | $(0.64) | $(0.61) |
| Cash and Cash Equivalents (End of Period) | $1,858,104 | $16,059 | $1,858,104 | $16,059 |
| Total Assets | $1,977,264 | $798,082 | $1,977,264 | $798,082 |
| Total Liabilities | $2,684,391 | $24,814,297 | $2,684,391 | $24,814,297 |
| Stockholders' Deficit | $(707,127) | $(24,016,215) | $(707,127) | $(24,016,215) |
Operating Expenses (YTD 2024 vs YTD 2023):
- Research & Development: $1,968,591 vs $2,197,936
- General & Administrative: $1,878,831 vs $987,677
Cash Flow (YTD 2024):
- Net cash used in operating activities: $(4,907,718)
- Net cash provided by financing activities: $6,726,840 (primarily from IPO and debt conversions)
Material Changes vs. Prior Period
- Capital Structure Transformation: On August 2, 2024, the Company completed its IPO, selling 1.6 million shares at $4.00 per share. Concurrently, all outstanding convertible notes (Groups A through F) and Series A Preferred Stock were converted into approximately 13.2 million shares of common stock. This eliminated approximately $14.5 million in convertible debt liabilities and $4.6 million in redemption premiums recorded as of December 31, 2023.
- Liquidity Improvement: Cash balances increased from $38,982 at year-end 2023 to $1,858,104 at September 30, 2024, driven by IPO proceeds and debt conversions.
- Expense Fluctuations: Q3 2024 operating expenses ($2.44M) were significantly higher than Q3 2023 ($0.62M), primarily due to increased General & Administrative costs ($1.23M vs $0.17M) related to marketing and accounting fees for the IPO. However, on a YTD basis, R&D expenses decreased slightly ($1.97M vs $2.20M) due to reduced vendor expenses for the Phase IIb trial and OST-tADC platform.
- Interest Expense Reduction: Interest expense decreased significantly in Q3 2024 ($0.44M) compared to Q3 2023 ($1.35M) as the convertible debt was converted to equity in August 2024, halting the amortization of debt discounts.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company states that its ability to continue as a going concern is dependent on obtaining additional capital. While the IPO provided liquidity, the Company expects to incur significant operating losses for the foreseeable future.
- Clinical Outlook: The Company expects topline results from its Phase 2 study of OST-HER2 in the fourth quarter of 2024. If successful, it intends to seek regulatory approval in 2025.
- Subsequent Financing: On October 31, 2024, the Company entered into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC, allowing the Company to sell up to $15 million of common stock over 24 months.
- Legal Proceedings: The Company settled an arbitration with Noble Capital Markets regarding an anti-dilution provision in September 2024, issuing 320,033 shares and $50,000 cash.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to a lack of segregation of duties and insufficient written policies.
- Commitments: The Company has significant future milestone payment obligations to Advaxis (up to $22.375M) and BlinkBio (up to $22.375M) contingent on regulatory approvals and sales milestones.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.86M cash balance against the projected burn rate, given the expectation of continued losses and the need for further capital raises.
- Dilution Impact: Review the impact of the recent conversion of debt and preferred stock (approx. 13.2M shares) and the new $15M Equity Purchase Agreement on future share count and dilution.
- Clinical Trial Results: Monitor the anticipated Q4 2024 topline results for the OST-HER2 Phase 2 study, which is critical for future funding and valuation.
- Internal Control Remediation: Assess the timeline and plan for remedying the material weaknesses in internal controls over financial reporting identified by management.
- Milestone Obligations: Evaluate the financial impact of potential future milestone payments to Advaxis and BlinkBio, which could total over $40M if regulatory and sales targets are met.